{"log_id": 1840924343954439982, "direction": 0, "words_result_num": 52, "words_result": [{"probability": {"variance": 0.001673, "average": 0.988247, "min": 0.756748}, "location": {"width": 826, "top": 158, "height": 46, "left": 179}, "words": "每日1次,连续服用26周(共90人)。试验的终点指标为左心室容积的改变是否等于或大"}, {"probability": {"variance": 0.007648, "average": 0.959717, "min": 0.580641}, "location": {"width": 826, "top": 189, "height": 43, "left": 180}, "words": "于10%。心功能3级和4级(NYHA分级患者未参加该试验,故罗格列酮不推荐用于这类病"}, {"probability": {"variance": 0.002021, "average": 0.98064, "min": 0.835964}, "location": {"width": 437, "top": 223, "height": 37, "left": 180}, "words": "人,除非其服用本品的预期疗效超过其潜危险"}, {"probability": {"variance": 0.014061, "average": 0.946297, "min": 0.431565}, "location": {"width": 790, "top": 244, "height": 43, "left": 220}, "words": "罗格列酮上市初期,有与容增加相关的不良反应报道(如:允血性心衰和肺水肿)"}, {"probability": {"variance": 1e-05, "average": 0.997017, "min": 0.990365}, "location": {"width": 118, "top": 288, "height": 24, "left": 202}, "words": "见水肿部分)"}, {"probability": {"variance": 0.000129, "average": 0.994921, "min": 0.937661}, "location": {"width": 787, "top": 298, "height": 44, "left": 220}, "words": "体重:本品单用和与其它服降糖药合用,可出现体重增加,且具有剂量相关性,体重增"}, {"probability": {"variance": 1.4e-05, "average": 0.997167, "min": 0.984947}, "location": {"width": 671, "top": 328, "height": 44, "left": 180}, "words": "加的机制尚不清楚,但可能为体液潴留和脂肪重新分布的共同作用的结果"}, {"probability": {"variance": 0.002667, "average": 0.98778, "min": 0.677514}, "location": {"width": 788, "top": 355, "height": 41, "left": 220}, "words": "肝脏反应:另一种噻唑烷二酮类化合物曲格列酮与特应性肝脏毒性有关,在其上市后临"}, {"probability": {"variance": 7e-06, "average": 0.998212, "min": 0.986048}, "location": {"width": 826, "top": 381, "height": 45, "left": 182}, "words": "床使用中,曾有极少数病例出现肝功能衰竭、肝移植或死亡。在上市前对照临床试验中,与"}, {"probability": {"variance": 0.0078, "average": 0.981163, "min": 0.42879}, "location": {"width": 827, "top": 410, "height": 42, "left": 184}, "words": "安慰剂相比,2型糖尿病患者在曲格列组出现有临床意义的肝酶升高(ALT>正常上限3"}, {"probability": {"variance": 0.000744, "average": 0.984681, "min": 0.907925}, "location": {"width": 453, "top": 444, "height": 35, "left": 184}, "words": "倍)的发生率高,且有极少数病例出现可逆性黄痘"}, {"probability": {"variance": 0.00082, "average": 0.990493, "min": 0.832259}, "location": {"width": 790, "top": 465, "height": 40, "left": 221}, "words": "多项临床试验中,共有4598例患者接受罗格列酮治疗,服用时间约为3600病人年,无"}, {"probability": {"variance": 4e-05, "average": 0.997443, "min": 0.959597}, "location": {"width": 817, "top": 492, "height": 41, "left": 192}, "words": "正据表明有药物所致的肝毒性反应或ALT水平升高发生。在罗格列酮上市初期,有极少数的"}, {"probability": {"variance": 9e-06, "average": 0.998293, "min": 0.983121}, "location": {"width": 628, "top": 523, "height": 38, "left": 180}, "words": "肝功异常(主要为肝酶升高)的报道。造成肝功异常的原因尚不确定"}, {"probability": {"variance": 2.3e-05, "average": 0.997574, "min": 0.974071}, "location": {"width": 763, "top": 548, "height": 40, "left": 222}, "words": "在对照试验中,ALT水平超过正常上限的3倍时的发生率分别为:罗格列酮组0.2%"}, {"probability": {"variance": 8.7e-05, "average": 0.996596, "min": 0.938219}, "location": {"width": 830, "top": 576, "height": 41, "left": 182}, "words": "安慰剂组0.2%,阳性对照组0.5%。服用罗格列酮患者的ALT升高均为可逆性,且与服用本"}, {"probability": {"variance": 8.6e-05, "average": 0.996064, "min": 0.968359}, "location": {"width": 209, "top": 616, "height": 30, "left": 182}, "words": "品的因果关系尚不确定"}, {"probability": {"variance": 0.017261, "average": 0.949513, "min": 0.359775}, "location": {"width": 786, "top": 632, "height": 40, "left": 224}, "words": "罗格列酮在化学结构上与曲格列相似,而格列酮与特应性肝脏毒性有关,曾有极少"}, {"probability": {"variance": 0.005693, "average": 0.972653, "min": 0.621689}, "location": {"width": 827, "top": 660, "height": 41, "left": 183}, "words": "数病例出现肝功能衰竭、肝移植或死亡鉴于尚无一些长期大规模的对照临床试验结果及上"}, {"probability": {"variance": 0.003341, "average": 0.97906, "min": 0.723594}, "location": {"width": 828, "top": 686, "height": 43, "left": 186}, "words": "市后大量临床应用的安全性资料以明确罗格列酮的肝脏安全性,故推荐服用本品的患者定期"}, {"probability": {"variance": 0.000436, "average": 0.991261, "min": 0.895413}, "location": {"width": 822, "top": 714, "height": 40, "left": 184}, "words": "监测肝功。病人开始服用本品前,应检测肝酶。若2型糖尿病患者血清转氨酶升高(ALT"}, {"probability": {"variance": 0.006318, "average": 0.982476, "min": 0.481198}, "location": {"width": 828, "top": 741, "height": 42, "left": 183}, "words": "正常上限的2.5倍)时,则不应服用本晶。对于肝酶基线正常的患者,建议在开始服用本品"}, {"probability": {"variance": 0.000119, "average": 0.997084, "min": 0.931532}, "location": {"width": 824, "top": 768, "height": 40, "left": 184}, "words": "后的12月内,每两个月检测一次肝功,之后定期检查,对于本品治疗前或治疗中肝酶略高"}, {"probability": {"variance": 0.000472, "average": 0.99084, "min": 0.89084}, "location": {"width": 809, "top": 794, "height": 40, "left": 202}, "words": "ALT为正常上限的1~2.5倍)的患者,应分析其肝酶升高的原因。对肝酶轻度升高的患"}, {"probability": {"variance": 0.00904, "average": 0.970101, "min": 0.466919}, "location": {"width": 827, "top": 821, "height": 43, "left": 184}, "words": "者,服用本品应慎重,逼当缩短临床链访时间,增加肝酶检测频率,以确定肝酶升高是否缓解"}, {"probability": {"variance": 0.003671, "average": 0.980195, "min": 0.674559}, "location": {"width": 825, "top": 849, "height": 40, "left": 184}, "words": "或加重。如果服用本品的患者ALT大于正常上限3倍时,则需尽快复查肝酶。若复查结果肝"}, {"probability": {"variance": 0.000551, "average": 0.991202, "min": 0.886799}, "location": {"width": 460, "top": 882, "height": 35, "left": 183}, "words": "酶仍大于正常上限3倍以上时,则应停止服用本品"}, {"probability": {"variance": 0.013096, "average": 0.966435, "min": 0.443807}, "location": {"width": 789, "top": 904, "height": 40, "left": 224}, "words": "尚无资料显示对于那些服用曲格列酮后出现肝脏病变、肝功异常或黄疸的患者服用本品"}, {"probability": {"variance": 0.000586, "average": 0.992045, "min": 0.849929}, "location": {"width": 827, "top": 927, "height": 45, "left": 186}, "words": "是否安全。服用曲格列酮后出现黄疸的患者不宜服用本品,对于服用曲格列酮后肝酶正常的"}, {"probability": {"variance": 0.000143, "average": 0.99416, "min": 0.94892}, "location": {"width": 481, "top": 962, "height": 36, "left": 185}, "words": "患者改服本品时,建议在服用本品前有一周的清洗期"}, {"probability": {"variance": 0.000507, "average": 0.991113, "min": 0.899392}, "location": {"width": 437, "top": 989, "height": 35, "left": 226}, "words": "如患者出现疑似肝功异常症状(不明原因的恶心"}, {"probability": {"variance": 0.023383, "average": 0.928353, "min": 0.533283}, "location": {"width": 267, "top": 983, "height": 31, "left": 746}, "words": "中痛。疲劳、厌食/或尿色加"}, {"probability": {"variance": 0.006875, "average": 0.974103, "min": 0.510602}, "location": {"width": 825, "top": 1013, "height": 38, "left": 184}, "words": "深)时,需检测肝酶。患者是否继续服药取决于实验检测果出现黄痕,则应停止服"}, {"probability": {"variance": 0, "average": 0.999902, "min": 0.999902}, "location": {"width": 25, "top": 1057, "height": 24, "left": 185}, "words": "药"}, {"probability": {"variance": 0, "average": 0.999753, "min": 0.999353}, "location": {"width": 106, "top": 1080, "height": 25, "left": 227}, "words": "实验室检查"}, {"probability": {"variance": 0.013775, "average": 0.961747, "min": 0.539727}, "location": {"width": 260, "top": 1102, "height": 32, "left": 225}, "words": "患者应定期检查血糖和HbAl"}, {"probability": {"variance": 0.000219, "average": 0.994309, "min": 0.934801}, "location": {"width": 398, "top": 1128, "height": 36, "left": 224}, "words": "病人开始服用本品前,应检测肝酶,之后定"}, {"probability": {"variance": 0, "average": 0.798114, "min": 0.798114}, "location": {"width": 415, "top": 1024, "height": 167, "left": 607}, "words": "冷"}, {"probability": {"variance": 3.9e-05, "average": 0.995911, "min": 0.976193}, "location": {"width": 254, "top": 1165, "height": 29, "left": 227}, "words": "65岁以上老年患者慎用本品"}, {"probability": {"variance": 0.001172, "average": 0.983431, "min": 0.90257}, "location": {"width": 239, "top": 1196, "height": 31, "left": 190}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.020144, "average": 0.9344, "min": 0.46282}, "location": {"width": 788, "top": 1213, "height": 43, "left": 226}, "words": "妊娠分类C:给予妊娠早期的大键罗格列酮,对着床影响,但在妊娠中晚期给"}, {"probability": {"variance": 0.001073, "average": 0.98859, "min": 0.802958}, "location": {"width": 828, "top": 1242, "height": 42, "left": 185}, "words": "药,可引起大鼠和家兔胚胎死亡和生长迟滞,分别给予大鼠和家兔罗格列酮3毫克/公斤和"}, {"probability": {"variance": 0.001093, "average": 0.988818, "min": 0.817587}, "location": {"width": 790, "top": 1270, "height": 41, "left": 186}, "words": "100毫克/公斤(分别相当于人口服最大推荐剂量AC的20和75倍),未发现致畸作用"}, {"probability": {"variance": 0.000957, "average": 0.98777, "min": 0.878595}, "location": {"width": 787, "top": 1296, "height": 42, "left": 226}, "words": "给予大鼠罗格列酮3毫克/公斤/日可引起其胎盘病变。大鼠妊娠和哺乳期间连续给药可"}, {"probability": {"variance": 0.000784, "average": 0.99077, "min": 0.824663}, "location": {"width": 828, "top": 1323, "height": 44, "left": 186}, "words": "引起窝仔数减少,新生鼠成活力下降和出生后生长迟滞,但生长迟滞可于青春期后改善。罗"}, {"probability": {"variance": 0.001158, "average": 0.983726, "min": 0.868022}, "location": {"width": 829, "top": 1352, "height": 42, "left": 186}, "words": "格列酮0.2毫克/公斤/日和15毫克/公斤/分别为大鼠和家兔的胎盘、胚胎/胎仔及子代无"}, {"probability": {"variance": 0.00264, "average": 0.983869, "min": 0.736846}, "location": {"width": 544, "top": 1385, "height": 37, "left": 188}, "words": "影响剂量,该剂量约相当于人日服最大推荐剂量AUC的4倍"}, {"probability": {"variance": 0.000144, "average": 0.994489, "min": 0.935836}, "location": {"width": 779, "top": 1405, "height": 45, "left": 229}, "words": "由于缺乏妊娠妇女用药资料,因此,除非所获利益大于对胎儿的潜在危险,否则妊娠"}, {"probability": {"variance": 1e-06, "average": 0.999071, "min": 0.996732}, "location": {"width": 212, "top": 1445, "height": 31, "left": 187}, "words": "女不应服用本品"}, {"probability": {"variance": 0.003153, "average": 0.984621, "min": 0.677986}, "location": {"width": 788, "top": 1461, "height": 43, "left": 227}, "words": "现有资料表明:妊娠期间血糖水平异常可增加新生儿先天性畸形的发生率、新生儿的发"}, {"probability": {"variance": 0.000241, "average": 0.994719, "min": 0.931213}, "location": {"width": 753, "top": 1490, "height": 42, "left": 189}, "words": "病率和死亡率,为此大多数专家推荐在妊娠期使用胰岛素,以尽可能保持血糖正常"}, {"probability": {"variance": 0.001166, "average": 0.982946, "min": 0.87231}, "location": {"width": 456, "top": 1522, "height": 37, "left": 229}, "words": "对分娩的影响:尚无罗格列酮对人分娩影响的资料"}], "language": 3}